Frontlight ResearchEarly access
Parkinson disease trials in France
19 of 65 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- No phaseActive, not recruitingRegistry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
- Where
- Créteil, Lyon, Marseille, Paris, Rennes
- Age
- 18 years and over
- People
- 1,500 worldwide
- Run by
- Boston Scientific Corporation
See details and how to joinNCT02071134 - No phaseTaking peopleDeep Brain Stimulation (DBS) Retrospective Outcomes Study
- Where
- Paris
- People
- 5,000 worldwide
- Run by
- Boston Scientific Corporation
See details and how to joinNCT03664609 - No phaseNot yet taking people in FrancePrimary Parkinsonian Pain: Clinical Association and Phenotype
- Where
- Clermont-Ferrand
- Age
- 18 years and over
- People
- 300
- Run by
- University Hospital, Clermont-Ferrand
See details and how to joinNCT07702266 - No phaseNot yet taking people in FranceArtificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) Study
- Where
- Toulouse
- Age
- 50 years and over
- People
- 60 worldwide
- Run by
- Queen Mary University of London
See details and how to joinNCT07706829 - No phaseTaking peopleThe Role of Priors in Hallucinatory Perception in Parkinson's Disease
- Where
- Grenoble, La Tronche
- Age
- 18 years to 85 years
- People
- 60
- Run by
- University Hospital, Grenoble
See details and how to joinNCT07427498 - No phaseNot yet taking people in FranceANCILLARY STUDY No. 3 NS-PARK-OMICS
- Where
- Paris
- Age
- 18 years and over
- People
- 80
- Run by
- Institut National de la Santé Et de la Recherche Médicale, France
See details and how to joinNCT07832461 - No phaseTaking peopleFrench Parkinson's Disease Cohort - NS-PARK
- Where
- Paris
- Age
- 10 years and over
- People
- 30,000
- Run by
- Institut National de la Santé Et de la Recherche Médicale, France
See details and how to joinNCT04888364 - No phaseTaking peopleInterest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life
- Where
- Crest
- Age
- 18 years and over
- People
- 80
- Run by
- Centre Hospitalier Régional d'Orléans
See details and how to joinNCT07257861 - No phaseTaking peopleAbbott DBS Post-Market Study of Outcomes for Indications Over Time
- Where
- Clermont-Ferrand, Nice, Paris, Saint-Etienne
- People
- 1,000 worldwide
- Run by
- Abbott Medical Devices
See details and how to joinNCT04071847 - No phaseTaking peopleIntegrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
- Where
- Marseille
- Age
- 18 years to 90 years
- People
- 700
- Run by
- Assistance Publique Hopitaux De Marseille
See details and how to joinNCT07202494 - No phaseNot yet taking people in FranceAI-based Progression and Medication Response Prediction Study in Parkinson's Disease
- Where
- Toulouse
- Age
- 40 years to 80 years
- People
- 100 worldwide
- Run by
- University Hospital, Toulouse
See details and how to joinNCT07189468 - No phaseTaking peopleTraining of Nursing Home Professionals and Quality of Life of Residents With Parkinson's Disease
- Where
- Grenoble
- Age
- 18 years and over
- People
- 90
- Run by
- University Hospital, Grenoble
See details and how to joinNCT06908460 - No phaseNot yet taking people in FranceOne-Year Effect on Levodopa Equivalent Daily Dose of Thalamic VIM Nucleus Stimulation Compared to Subthalamic Nucleus Stimulation in Patients With Parkinson's Disease
- Where
- Nancy
- People
- 94
- Run by
- Central Hospital, Nancy, France
See details and how to joinNCT06936254 - No phaseCompletedInternational Validation of Two Non-motor Scales in PD (NFS and SPARK)
- Where
- Besançon
- Age
- 30 years to 75 years
- People
- 300 worldwide
- Run by
- Insel Gruppe AG, University Hospital Bern
See details and how to joinNCT04366804 - No phaseNot yet taking people in FranceTrial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
- Where
- Besançon, Bron, Clermont-Ferrand, Créteil, Grenoble, Lille, Limoges, Marseille, Nantes, Paris, Poitiers, Reims, Rennes, Rouen, Strasbourg, Toulouse
- Age
- 35 years to 75 years
- People
- 100
- Run by
- University Hospital, Strasbourg, France
See details and how to joinNCT06754553 - No phaseTaking peopleTowards the Validation of a New Blood Biomarker for the Early Diagnosis of Parkinson's Disease
- Where
- Grenoble
- Age
- 18 years and over
- People
- 70
- Run by
- University Hospital, Grenoble
See details and how to joinNCT05385315 - No phaseTaking peopleMovement Error-processes and Sensorimotor Adaptation in Parkinsonian Patient
- Where
- Marseille
- Age
- 18 years and over
- People
- 100
- Run by
- Assistance Publique Hopitaux De Marseille
See details and how to joinNCT03371407 - No phaseTaking peopleCerebro Spinal Fluid Collection (CSF)
- Where
- Strasbourg
- People
- 10,000
- Run by
- University Hospital, Strasbourg, France
See details and how to joinNCT04844060 - No phaseNot yet taking people in FranceSystematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)
- Where
- Strasbourg
- Age
- 21 years and over
- People
- 150
- Run by
- University Hospital, Strasbourg, France
See details and how to joinNCT05072015